Anest. intenziv. Med. 2014;25(3):203-211

The role of ultrashort-acting beta-blockers in anaesthesia and intensive careAnaesthesiology - Review articles

Rulíšek Jan*, Balík Martin, Leden Pavel, Zakharchenko Mikhailo
Klinika anesteziologie resuscitace a intenzivní medicíny, 1. LF UK a VFN v Praze

Beta-1-adrenergic blocking agents are widely used in patients with ischaemic heart disease and patients with heart failure. Anaesthesiologists are in daily contact with these drugs as they are part of medication in anaesthetised patients undergoing surgical procedures. Long-term mortality benefit effect of these drugs has been proven. Esmolol as a representative of ultrashort-acting beta-blockers can be safely used to control septic tachycardia and promote myocardial protection in this situation. According to published data it can be used even if a patient has concomitant catecholamine infusion. In the peri-operative period, esmolol is indicated for short time haemodynamic suppression, for example in patients undergoing pheochromocytoma resection. In cardiac surgical patients, peri-operative infusion of esmolol led to better post-reperfusion myocardial adaptation. This article reviews the indications for esmolol with special attention to its use in septic patients.

Keywords: Esmolol; septic tachycardia; septic shock; beta-1-blocking agent

Received: October 29, 2013; Accepted: March 1, 2014; Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rulíšek J, Balík M, Leden P, Mikhailo Z. The role of ultrashort-acting beta-blockers in anaesthesia and intensive care. Anest. intenziv. Med. 2014;25(3):203-211.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Freemantle, N. et al. Beta blockade after myocardial infarction: systemic review and meta regression analysis. Br. Med. J., 1999, 318, p. 1730-1737. Go to original source... Go to PubMed...
    2. Fonarow, G. C. et al. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). Am. Heart J., 2007, 154 (4), p. 637-644. Go to original source... Go to PubMed...
    3. Deedwania, P. C. MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am. Heart. J., 2005, 149 (1), p. 159-167. Go to original source... Go to PubMed...
    4. Mangano, D. T. et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N. Engl. J. Med., 1996, 5, 335 (23), p. 1713-1720. Go to original source... Go to PubMed...
    5. Rojas, Y. et al. Burns: an update on current pharmacotherapy. Expert Opin. Pharmacother., 2012, 13 (17), p. 2485-2494. Go to original source... Go to PubMed...
    6. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference. Definitions of sepsis and organ failure and Guidelines for the use of innovative therapies in sepsis. Crit. Care. Med., 1992, 20, p. 864-874. Go to PubMed...
    7. Pitted, D. et al. Efficacy and safety of human activated protein C for severe sepsis. Am. J. Respir. Crit. Care, 1999, 160, p. 852-857. Go to original source... Go to PubMed...
    8. Bernard, G. et al. Efficacy and safety of human rhAPC for severe sepsis. N. Engl. J. Med., 2001, 344, p. 749-762. Go to original source... Go to PubMed...
    9. Warren, B. L. et al. Caring for the critically ill patient. High dose antithrombin III in severe sepsis: A randomised controlled trial. JAMA, 2001, 286, p. 1869-1878. Go to original source... Go to PubMed...
    10. Vieillard-Baron, A. et al. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit. Care Med., 2008, 36 (6), p. 1701-1706. Go to original source... Go to PubMed...
    11. Bouhemad, B. et al. Isolated and reversible impairment of ventricular relaxation in patients with septic shock. Crit. Care Med., 2008, 36 (3), p. 766-774. Go to original source... Go to PubMed...
    12. Kumar, A. et al. Tumor necrosis factor-alpha and interleukin 1-beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J. Exp. Med., 1996, 2, p. 949-958. Go to original source... Go to PubMed...
    13. Tracey, K. J. et al. Shock and tissue injury induced by recombinant human cachectin. Science, 1986, 234, p. 470-474. Go to original source... Go to PubMed...
    14. Finkel, M. S. et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science, 1992, 257, p. 387-389. Go to original source... Go to PubMed...
    15. Murray, D. R. et al. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ. Res., 1995, 78, p. 154-160. Go to original source... Go to PubMed...
    16. Okusawa, S. et al. Interleukin 1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. 1988, 81, p. 162-172. Go to original source...
    17. Schulz, R. et al. The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumor necrosis factor-alpha. Br. J. Pharmacol., 1995, 114, p. 27-34. Go to original source... Go to PubMed...
    18. Opal, S. M. et al. Confirmatory interleukin 1 receptor antagonist trial in severe sepsis: A phase III randomised double blind, placebo-controled multicenter trial. Crit. Care Med., 1997, 25, p. 1115-1124. Go to original source... Go to PubMed...
    19. Winslow, E. J. et al. Hemodynamic studies and results of therapy in 50 patients with bacteremic shock. Am. J. Med., 1973, 54, p. 421-432. Go to original source... Go to PubMed...
    20. Krausz, M. M. et al. Cardiopulmonary effects of volumeloading in patients with septic shock. Am. Surg., 1977, 185, p. 429-434. Go to original source... Go to PubMed...
    21. Parker, S. M. et al. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit. Care Med., 1987, 15, p. 923-929. Go to original source... Go to PubMed...
    22. Ahmed, A. J. et al. Hemodynamic responses to gram-positive versus gram-negative sepsis in critically ill patients with and without circulatory shock. Crit. Care Med., 1991, 19, p. 1520-1525. Go to original source... Go to PubMed...
    23. Shoemaker, W. C. et al. Clinical trial of survivors cardiorespiratory patterns as therapeutic goals in critically ill postoperative patients. Crit. Care Med., 1982, 10, p. 398-403. Go to original source... Go to PubMed...
    24. Shoemaker, W. C., Appel, P. L., Kram, H. B. et al. Prospective trial of supranormal values of survivors as therapeutic goals in high risk surgical patients. Chest, 1988, 94, p. 1176-1186. Go to original source... Go to PubMed...
    25. Rivers, E. et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med., 2001, 345, p. 1368-1377. Go to original source... Go to PubMed...
    26. Gattinoni, L. et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N. Engl. J. Med., 1995, 333, p. 1025-1032. Go to original source... Go to PubMed...
    27. Hayes, M. A. et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N. Engl. J. Med., 1994, 330, p. 1717-1722. Go to original source... Go to PubMed...
    28. Dyson, A., Rudiger, A., Singer, M. et al. Temporal changes in tissue cardiorespiratory function during foecal perinotitis. Intensive Care Med., 2011, 37, p. 1192-200. Go to original source... Go to PubMed...
    29. Levy, B., Bollaert, P. E. et al. Comparison of norepinephrine and dobutamine to epinphrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med., 1997, 23, p. 282-287. Go to original source... Go to PubMed...
    30. Gore, D. C. et al. Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Ann. Surg., 1996, 224, p. 97-102. Go to original source... Go to PubMed...
    31. Ronco, J. J. et al. Oxygen consumption is independent of increases in oxygen delivery by dobutamine in septic patients who have normal or increased plasma lactate. Am. Rev. Respir. Dis., 1993, 147, p. 25-31. Go to original source... Go to PubMed...
    32. Tracey, K. J et al. Shock and tissue injury induced by recombinant human cachectin. Science, 1986, 234, p. 470-474. Go to original source... Go to PubMed...
    33. Finkel, M. S. et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science, 1992, 257, p. 387-389. Go to original source... Go to PubMed...
    34. Murray, D. R., Freeman, G. L. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ. Res., 1995, 78, p. 154-160. Go to original source... Go to PubMed...
    35. Okusawa, S. et al. Interleukin 1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest., 1988, 81, p. 1162-1172. Go to original source... Go to PubMed...
    36. Schulz, R et al. The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumor necrosis factor-alpha.Br. J. Pharmacol., 1995, 114, p. 27-34. Go to original source... Go to PubMed...
    37. Kumar, A., Thota, V., Dee, L. et al. Tumor necrosis factor-alpha and interleukin 1-beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J. Exp. Med., 1996, 2, p. 949-958. Go to original source... Go to PubMed...
    38. Prabhu, S. D. et al. Beta-adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide and remodeling. Circulation, 2000, 101, p. 2103-2109. Go to original source... Go to PubMed...
    39. Kapadia, S., Lee, J., Amione, G. T. et al. Tumor necrosis factor alpha gene and protein expression in adult feline myocardium after endotoxin administration. J. Clin. Invest., 1995, 96, p. 1042-1052. Go to original source... Go to PubMed...
    40. Prabhu, S. D. et al. Beta-adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide and remodeling. Circulation, 2000, 101, p. 2103-2109. Go to original source... Go to PubMed...
    41. Cunnion, R. E., Schaer, G. L., Parker, M. M. et al. The coronary circulation in human septic shock. Circulation, 1986, 73(4), p. 637-644. Go to original source... Go to PubMed...
    42. Parker, M. M. et al. Profound but reversible myocardial depression in patients with septic shock. Ann. Intern. Med., 1984, 100, p. 483-490. Go to original source... Go to PubMed...
    43. Poelaert, J. et al. Left ventricular systolic and diastolic function in septic shock. Intensive Care Med., 1997, 23, p. 553-560. Go to original source... Go to PubMed...
    44. Munt, B. et al. Diastolic filling in human severe sepsis: an echocardiographic study. Crit. Care Med., 1998, 26, p. 1829-1833. Go to original source... Go to PubMed...
    45. Suzuki, T. et al. Infusion of beta adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit. Care. Med., 2005: 33: 2294-2301. Go to original source... Go to PubMed...
    46. Aboab, J. et al. Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock. Intensive Care Med., 2011, 37(8), p. 1344-1351. Go to original source... Go to PubMed...
    47. Balik, M., Rulisek, J., Leden, P. et al. Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Wien Klin. Wochenschr., 2012, 124 (15-16), p. 552-556. Go to original source... Go to PubMed...
    48. Morelli, A. et al. Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit. Care Med., 2013, 41 (9), p. 2162-2168. Go to original source... Go to PubMed...
    49. Morelli, A. et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA, 2013, 310 (16), p. 1683-1691. Go to original source... Go to PubMed...
    50. Rodríguez González, O. et al. Esmolol to control hemodynamic response during removal of a bilateral pheochromocytoma from a 10-year-old girl. Rev. Esp. Anestesiol. Reanim., 2010, 57 (7), p. 454-457. Go to original source...
    51. Latendresse, T. R. et al. Anesthesia for pheochromocytoma resection in a child with Fontan circulation. Anaesth., 2011, 58 (7), p. 642-645. Go to original source... Go to PubMed...
    52. Zakowski, M. et al. Esmolol use during resection of pheo-chromocytoma: report of three cases. Anesthesiology, 1989, 70(5), p. 875-877. Go to original source... Go to PubMed...
    53. Shen, P. H. et al. Intravenous esmolol infusion improves surgical fields during sevoflurane-anesthetized endoscopic sinus surgery: a double-blind, randomized, placebo-controlled trial, Am. J. Rhinol. Allergy., 2011, 25 (6), p. 208-211. Go to original source... Go to PubMed...
    54. Ibraheim, O. A. et al. Esmolol versus dexmedetomidine in scoliosis surgery: study on intraoperative blood loss and hemodynamic changes. Middle East J. Anesthesiol., 2013, 22 (1), p. 27-33.
    55. Landoni, G., Crescenzi, G., Zangrillo, A. et al. Validation of a decision-making strategy for systolic anterior motion following mitral valve repair. Ann. Card. Anaesth., 2011, 14 (2), p. 85-90. Go to original source... Go to PubMed...
    56. Landoni, G. et al. Esmolol reduces perioperative ischemia in noncardiac surgery: a meta-analysis of randomized controlled studies. J. Cardiothorac. Vasc. Anesth., 2010, 24 (2), p. 219-229. Go to original source... Go to PubMed...
    57. Lee, S. J., Lee, J. N. The effect of perioperative esmolol infusion on the postoperative nausea, vomiting and pain after laparoscopic appendectomy. Korean J. Anesthesiol., 2010, 59 (3), p. 179-184. Go to original source... Go to PubMed...
    58. Sun, J., Ding, Z., Qian, Y. Effect of short-acting beta blocker on the cardiac recovery after cardiopulmonary bypass.J. Cardiothorac. Surg., 2011, 6, p. 99. Go to original source... Go to PubMed...
    59. Hilleman, D. E. et al. Esmolol versus diltiazem in atrial fibrillation following coronary artery bypass graft surgery. Curr. Med. Res. Opin., 2003, 19 (5), p. 376-382. Go to original source... Go to PubMed...
    60. Guarracino, F. et al. β-Blockers to optimize peripheral oxygenation during extracorporeal membrane oxygenation: a case series. J. Cardiothorac. Vasc. Anesth., 2012, 26 (1), p. 58-63. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.